Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Congenital heart defect.
• Age ≥ 18 years.
• Initiated on treatment with an SGLT2i.
Locations
United States
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Michigan
Helen DeVos Children's Hospital
NOT_YET_RECRUITING
Grand Rapids
New York
Mount Sinai Fuster Heart Hospital
RECRUITING
New York
Other Locations
Netherlands
Amsterdam University Medical Center
RECRUITING
Amsterdam
Leiden University Medical Center (LUMC)
RECRUITING
Leiden
University Medical Center Utrecht
RECRUITING
Utrecht
United Kingdom
University Hospital of Wales
RECRUITING
Cardiff
Golden Jubilee University National Hospital
RECRUITING
Glasgow
Barts Heart Centre
RECRUITING
London
Contact Information
Primary
Ralph M.L. Neijenhuis, MD
r.m.l.neijenhuis@lumc.nl
+31 71 5262020
Backup
Anastasia D. Egorova, MD PhD
a.egorova@lumc.nl
+31 71 5262020
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 400
Treatments
ACHD patients treated with SGLT2i
All participants included in the registry have to have a congenital heart defect, be ≥ 18 years old, and receive (or have received) treatment with SGLT2i.
Related Therapeutic Areas
Sponsors
Leads: Leiden University Medical Center